Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
  • Published Date:
    March 13 2019
  • Source:
    PLoS One. 14(3)
  • Language:
    English
Filetype[PDF-470.26 KB]


Details:
  • Alternative Title:
    PLoS One
  • Personal Author:
  • Description:
    Objectives

    To investigate treatment outcomes and associated characteristics of persons experiencing homelessness who received 12-weekly doses of directly observed isoniazid and rifapentine (3HP/DOT) treatment for latent TB infection (LTBI).

    Methods

    Among homeless persons treated with 3HP/DOT during July 2011 –June 2015 in 11 U.S. TB programs, we conducted descriptive analyses of observational data, and identified associations between sociodemographic factors and treatment outcomes. Qualitative interviews were conducted to understand programmatic experiences.

    Results

    Of 393 persons experiencing homelessness (median age: 50 years; range: 13–74 years), 301 (76.6%) completed treatment, 55 (14.0%) were lost to follow-up, 18 (4.6%) stopped because of an adverse event (AE), and 19 (4.8%) stopped after relocations or refusing treatment. Eighty-one (20.6%) had at least one AE. Persons aged ≥65 were more likely to discontinue treatment than persons aged 31–44 years. Programs reported difficulty in following up with persons experiencing homelessness because of relocations, mistrust, and alcohol or drug use.

    Conclusions

    This study demonstrates the feasibility of administering the 3HP/DOT LTBI regimen to persons experiencing homelessness, a high-risk population.

  • Subject:
  • Pubmed ID:
    30865724
  • Pubmed Central ID:
    PMC6415837
  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
  • Main Document Checksum:
No Related Documents.
You May Also Like:
  1. High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis Infection
    Personal Author:
    Sandul, Amy L.; Nwana, Nwabunie; Holcombe, J. Mike; Lobato, Mark N.; Marks, Suzanne; Webb, Risa; Wang, Shu-Hua; Stewart, Brock; Griffin, Phil; Hunt, Garrett; Shah, Neha; Marco, Asween; Patil, Naveen; Mukasa, Leonard; Moro, Ruth N.; Jereb, John; Mase, Sundari; Chorba, Terence; Bamrah-Morris, Sapna; Ho, Christine S.;
    Published Date:
    Oct 01 2017
    Source:
    Clin Infect Dis. 65(7):1085-1093.
    Description:
    BackgroundRCTs demonstrated the newest LTBI regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), as efficacious as 9 months of isoniazid (9H) with a greater completion rate (82% versus 69%); however, 3HP has not been assesse...
    File Type:
    Filetype[PDF - 621.18 KB]
  2. Public Health Response to Tuberculosis Outbreak among Persons Experiencing Homelessness, Minneapolis, Minnesota, USA, 2017–2018
    Personal Author:
    Tibbetts, Kelzee K.; Ottoson, Randy A.; Tsukayama, Dean T.;
    Published Date:
    Mar 2020
    Source:
    Emerg Infect Dis. 26(3):420-426
    Description:
    Tuberculosis (TB) is a greater risk for populations experiencing homelessness. When a TB exposure occurs in a homeless shelter, evaluation of contacts is both urgent and challenging. In 2017, local public health workers initiated a response to a TB o...
    File Type:
    Filetype[PDF - 633.56 KB]
  3. Use of Video Directly Observed Therapy for Treatment of Latent Tuberculosis Infection — Johnson County, Kansas, 2015
    Personal Author:
    Holzschuh, Elizabeth Lawlor; Province, Stacie; Johnson, Krystle; Walls, Caitlin; Shemwell, Cathy; Martin, Gary; Showalter, Amy; Dunlay, Jennifer; Conyers, Andrew; Griffin, Phil; Tausz, Nancy;
    Published Date:
    Apr 14 2017
    Source:
    MMWR Morb Mortal Wkly Rep. 66(14):387-389.
    Description:
    Tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis and is spread from person to person through the air. TB can be spread in congregate settings, such as school environments, to varying degrees, based on factors including duration...
    File Type:
    Filetype[PDF - 83.04 KB]
  4. Improved treatment completion with shorter treatment regimens for latent tuberculous infection
    Personal Author:
    Macaraig, M. M.; Jalees, M.; Lam, C.; Burzynski, J.;
    Published Date:
    November 01 2018
    Source:
    Int J Tuberc Lung Dis. 22(11):1344-1349
    Description:
    SETTING:Four New York City (NYC) Health Department tuberculosis (TB) clinics.OBJECTIVE:To assess the effectiveness of preferentially offering two shorter treatment regimens—4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and r...
    File Type:
    Filetype[PDF - 436.27 KB]
  5. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons
    Personal Author:
    Schmit, Kristine M.; Lobato, Mark N.; Lang, Simona G.; Wheeler, Sherri; Kendig, Newton E.; Bur, Sarah;
    Published Date:
    2019 Mar/Apr
    Source:
    J Public Health Manag Pract. 25(2):E1-E6
    Description:
    Context:Correctional facilities provide unique opportunities to diagnose and treat persons with latent tuberculosis infection (LTBI). Studies have shown that 12 weekly doses of isoniazid and rifapentine (INH-RPT) to treat LTBI resulted in high comple...
    File Type:
    Filetype[PDF - 316.10 KB]